JPRN-UMIN000010709已完成2 期
Phase II trial of gefitinib plus pemetrexed after the relapse to gefitinib in the patients with non-small-cell lung cancer harboring EGFR gene mutations. - Phase II trial of gefitinib plus pemetrexed after the relapse to gefitinib in the patients with non-small-cell lung cancer harboring EGFR gene mutations.
Hanshin-Saga Collaborative Cancer Study Group0 个研究点目标入组 45 人开始时间: 2013年5月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Prior chemotherapy or other systemic anti-cancer treatment (excluding EGFR TKIs). 2. Not considered to require radiotherapy to the lung at the time of study entry or in the near future. 3. Patients with past history of acute lung disorder or interstitial pneumonia, drug-induced interstitial disease or radiation pneumonitis requiring steroid therapy. Or those presenting the signs of comorbidity of acute disorder or interstitial pneumonia, or those having clear interstitial pneumonia or pulmonary fibrosis on chest CT. 4. Patients with large amount of or uncontrollable pleural effusion/ascites/pericardial fluid. 5. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy. 6. Patients with past history of serious drug allergy. 7. Concomitant use of CYP3A4 inducers eg phenytoin, carbamazepine, rifampicin, barbiturates or St John's Wort. 8. Patients with serious infectious disease or other serious complications. 9. As judged by the investigator, any evidence of severe or uncontrolled systemic disease. 10. Patients with complication by poorly controllable diabetes mellitus. 11. Known or suspected brain metastases or spinal cord compression, unless treated with surgery and/or radiation and stable without steroid treatment for at least 4 weeks prior to the first dose of study medication. 12. Patients with active double cancer. Or those who have been diagnosed as having malignant tumor within the past 5 years. 13. Patients with clinically problematic mental disorder, etc. 14. Patients who are pregnant, lactating or may be pregnant, or those who have no intention of contraception. 15. Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment. 16. Patients who are involved in the planning and practice of this study. 17. Previous enrolment or treatment in the present study. 18. Other patients who have been judged by attending physicians, etc. as being inappropriate for safe conduction of this study.
研究者
相似试验
已完成
2 期
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
进行中（未招募）
不适用
Phase II Study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC.Advanced Non Small-Cell Lung CarcinomaMedDRA version: 7.0Level: LLTClassification code 10061873EUCTR2004-001332-23-BEEuropean Organisation for Research and Treatment of Cancer55
招募中
2 期
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cancenon small cell lung cancerJPRN-UMIN000013586BAGEL study group90
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33